Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Personalis, Inc. is a cancer genomics company that develops and markets advanced tests and services for cancer detection and monitoring. Their main products include liquid biopsy tests like NeXT Personal for minimal residual disease (MRD) detection and tissue-based services like ImmunoID NeXT for a multi-dimensional tumor analysis. These solutions are utilized by pharmaceutical companies for research and clinical trials, and by physicians for patient therapy selection and monitoring.
AI-generated summary. Not investment advice.